{
  "title": "With 1 Million Dead Worldwide, The Latest On A Coronavirus Vaccine",
  "description": "With 10 vaccine candidates now in phase three trials, one expert predicts another million people worldwide could die within three to six months.<br/><br/>One of those vaccine candidates is produced by Novavax. Dr. Gregory Glenn, head of research and development for Novavax, <a href=\"https://www.npr.org/sections/coronavirus-live-updates/2020/09/25/916957152/novavax-researcher-says-no-chance-of-a-shortcut-in-vaccine-safety\">tells NPR he's not concerned about politics</a> tainting the vaccine approval process.<br/><br/>While the world waits for a vaccine, NPR science reporter <a href=\"https://www.npr.org/people/348778932/michaeleen-doucleff\">Michaeleen Doucleff</a> reports on a small but growing number of scientists asking: what if we already have <a href=\"https://www.npr.org/2020/09/29/918080914/scientists-experiment-with-tb-vaccine-to-see-if-it-slows-spread-of-covid-19\">a vaccine that could slow the spread of the virus? </a><br/><br/><a href=\"https://www.npr.org/sections/npr-extra/2020/09/09/909126490/where-you-can-hear-a-localized-consider-this\">In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.</a><br/><br/>We're working on an upcoming episode about pandemic precautions and we want to hear from you. <a href=\"https://www.npr.org/2020/09/28/917745021/6-months-into-the-pandemic-what-feels-safe-to-you-what-are-you-unsure-about\">Fill out the form on this page</a> and we may follow up on your response. <br/><br/>Email us at <a href=\"mailto:considerthis@npr.org\">considerthis@npr.org</a>.",
  "pubDate": "Tue, 29 Sep 2020 17:29:26 -0400",
  "copyright": "Copyright 2020-2021 NPR - For Personal Use Only",
  "guid": "cdc4ee39-4960-4727-a59e-be75aaa7e84d",
  "link": "https://www.npr.org/2020/09/28/917757050/with-1-million-dead-worldwide-the-latest-on-a-coronavirus-vaccine",
  "itunes:title": "With 1 Million Dead Worldwide, The Latest On A Coronavirus Vaccine",
  "itunes:author": "NPR",
  "itunes:summary": "With 10 vaccine candidates now in phase three trials, one expert predicts another million could die within three to six months.",
  "itunes:subtitle": "With 10 vaccine candidates now in phase three trials, one expert predicts another million could die within three to six months.",
  "itunes:image": "",
  "itunes:duration": 715,
  "itunes:explicit": "no",
  "itunes:episodeType": "full",
  "content:encoded": "With 10 vaccine candidates now in phase three trials, one expert predicts another million people worldwide could die within three to six months.<br/><br/>One of those vaccine candidates is produced by Novavax. Dr. Gregory Glenn, head of research and development for Novavax, <a href=\"https://www.npr.org/sections/coronavirus-live-updates/2020/09/25/916957152/novavax-researcher-says-no-chance-of-a-shortcut-in-vaccine-safety\">tells NPR he's not concerned about politics</a> tainting the vaccine approval process.<br/><br/>While the world waits for a vaccine, NPR science reporter <a href=\"https://www.npr.org/people/348778932/michaeleen-doucleff\">Michaeleen Doucleff</a> reports on a small but growing number of scientists asking: what if we already have <a href=\"https://www.npr.org/2020/09/29/918080914/scientists-experiment-with-tb-vaccine-to-see-if-it-slows-spread-of-covid-19\">a vaccine that could slow the spread of the virus? </a><br/><br/><a href=\"https://www.npr.org/sections/npr-extra/2020/09/09/909126490/where-you-can-hear-a-localized-consider-this\">In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.</a><br/><br/>We're working on an upcoming episode about pandemic precautions and we want to hear from you. <a href=\"https://www.npr.org/2020/09/28/917745021/6-months-into-the-pandemic-what-feels-safe-to-you-what-are-you-unsure-about\">Fill out the form on this page</a> and we may follow up on your response. <br/><br/>Email us at <a href=\"mailto:considerthis@npr.org\">considerthis@npr.org</a>.",
  "enclosure": ""
}